SCHEMBL24980449

SCHEMBL24980449

COc1cncc(NS(=O)(=O)c2ccc(S(=O)(=O)F)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 3/20 0.59
SLC22A12 Q96S37 1/20 0.57
CYP19A1 P11511 1/20 0.51
KEAP1 Q14145 1/20 0.50
NFE2L2 Q16236 1/20 0.50
HTR6 P50406 1/20 0.50
GAA P10253 2/20 0.49
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALPL P05186 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
PKM P14618 1/20 0.48
MAPK1 P28482 1/20 0.48
PIK3CA P42336 2/20 0.46
PIK3CD O00329 1/20 0.46
PIK3CG P48736 1/20 0.46
KMT2A Q03164 1/20 0.46
AKT1 P31749 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23547108 0.88 PIK3CB (0.59) PIK3CBSLC22A12CYP19A1KEAP1NFE2L2
SCHEMBL22792319 0.86 SLC22A12 (0.63) PIK3CBSLC22A12CYP19A1KEAP1NFE2L2
SCHEMBL23547109 0.83 SLC22A12 (0.52) PIK3CBSLC22A12CYP19A1KEAP1NFE2L2
SCHEMBL24980451 0.76 MEN1 (0.65) SLC22A12LMNASMN1; SMN2ALDH1A1TSHR
SCHEMBL22792095 0.74 GAA (0.58) SLC22A12CYP19A1KEAP1NFE2L2GAA
SCHEMBL31011104 0.73 SLC22A12 (0.51) PIK3CBSLC22A12GAALMNASMN1; SMN2
SCHEMBL17858621 0.72 MEN1 (0.60) PIK3CBSLC22A12GAALMNASMN1; SMN2
SCHEMBL15648607 0.70 PIK3CB (0.54) PIK3CBCYP19A1KEAP1NFE2L2GAA
SCHEMBL1055634 0.70 MEN1 (0.65) SLC22A12GAAALPLKMT2A
SCHEMBL790294 0.70 GAA (0.86) CYP19A1KEAP1NFE2L2GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230032020-A1 SMALL-MOLECULE COVALENT INHIBITION OF RAL GTPASES NATIONAL INSTITUTES OF HEALTH 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230032020-A1 SMALL-MOLECULE COVALENT INHIBITION OF RAL GTPASES RALA, KRAS, HRAS PIK3CB 1170/4885SLC22A12 2727/4885CYP19A1 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.